Video

Dr. Lavery on Achieving Safe Care for Esophagogastric Cancer During COVID-19

Anita Lavery, MD, MRCP, discusses achieving safe care for patients with esophagogastric cancer during the COVID-19 pandemic.

Anita Lavery, MD, MRCP, a medical oncology registrar at Queen’s University Belfast, discusses achieving safe care for patients with esophagogastric cancer during the COVID-19 pandemic.

Steps are already being taken in the United Kingdom to better care for this patient population through the British Society of Gastroenterology, Lavery explains. The organization issued a report in January 2021 explaining how gastrointestinal oncologists can move forward during the pandemic, as well as improve care for patients with gastrointestinal malignancies as more individuals are vaccinated and services begin to reopen.

One of the factors under investigation is the best way to prioritize patients due to the backlog of those who require care or services. Ideally, endoscopies would have been performed earlier, therefore prioritizing, and accelerating care for these patients is important, Lavery says. Additionally, vaccinating patients who need to come to the clinic for endoscopies is another process of interest, though it has not yet been implemented, Lavery concludes.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.